Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Background Tivantinib is a non-ATP competitive inhibitor of c-MET receptor tyrosine kinase that may have additional cytotoxic mechanisms including tubulin inhibition. Prostate cancer demonstrates higher c-MET expression as the disease progresses to more advanced stages and to a castration resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Paul, Liu, Glenn, Stadler, Walter M., Geyer, Susan, Huang, Ying, Wright, John, Villalona-Calero, Miguel, Wade, James, Szmulewitz, Russell, Gupta, Shilpa, Mortazavi, Amir, Dreicer, Robert, Pili, Roberto, Dawson, Nancy, George, Saby, Garcia, Jorge A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153554/
https://www.ncbi.nlm.nih.gov/pubmed/30083962
http://dx.doi.org/10.1007/s10637-018-0630-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153554/
https://www.ncbi.nlm.nih.gov/pubmed/30083962
http://dx.doi.org/10.1007/s10637-018-0630-9

Ejemplares similares